83 253

Cited 14 times in

Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis

Authors
Chae, S; Kim, YB; Lee, JS; Cho, H
Citation
American journal of physiology. Gastrointestinal and liver physiology, 302(9):G1016-G1024, 2012
Journal Title
American journal of physiology. Gastrointestinal and liver physiology
ISSN
0193-18571522-1547
Abstract
Hepatocellular carcinoma (HCC) generally shows chemoresistant features to anticancer agents. Paclitaxel has been clinically used in the treatment of various cancers. However, effect of paclitaxel on HCC has not been adequately addressed. Here, we found two categories of hepatoma cells in response to paclitaxel. Paclitaxel effectively decreased the cell viability of SNU475, Hep3B, and SNU387 HCC cells and Chang liver cells (death prone). In contrast, the other five hepatoma cell lines (SNU449, SNU398, SUN368, SNU354, and HepG2 cells) were resistant to paclitaxel (death reluctant). In response to paclitaxel, Bcl-2 was highly phosphorylated in death-prone cells, whereas much less Bcl-2 was phosphorylated in death-reluctant cells. Cotreatment with SP600125, an inhibitor JNK, significantly reduced the phosphorylated Bcl-2 in death-prone cells and caused a significant reduction in cell death. The reduced cell death was due to prohibition into mitotic entry as evidenced by low cyclin B(1)/Cdk1 kinase activity. In death-reluctant cells, inbuild-phospho-JNK levels were high but no longer activated in response to paclitaxel. We found that paclitaxel combined with caffeine or UCN-01, inhibitors of G(2) DNA damage checkpoint, was able to partially overcome resistance to paclitaxel in these cells. Thus our data provide the molecular basis of paclitaxel resistance in hepatoma cells, and appropriate combination therapy may increase treatment efficacy.
MeSH terms
Antineoplastic Agents/administration & dosageCarcinoma, Hepatocellular/*drug therapy/*metabolism/pathologyCell Line, TumorCell Survival/drug effectsDrug Resistance, Neoplasm/*geneticsEnzyme Activation/drug effectsHumansLiver Neoplasms/*drug therapy/*metabolism/pathologyMAP Kinase Kinase 4/*drug effectsMitosis/drug effects/*physiologyPaclitaxel/*administration & dosageTreatment Outcome
DOI
10.1152/ajpgi.00449.2011
PMID
22323130
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Biochemistry & Molecular Biology
Journal Papers > Research Organization > Institute for Medical Sciences
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
AJOU Authors
채, 선영김, 영배조, 혜성
Full Text Link
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse